• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    3/14/24 1:31:16 PM ET
    $AMIX
    $APM
    $BTTX
    $CLSD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMIX alert in real time by email

    Gainers

    • Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. The company's market cap stands at $21.2 million.
    • Aptorum Gr (NASDAQ:APM) stock moved upwards by 43.65% to $6.22. The market value of their outstanding shares is at $32.2 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock moved upwards by 17.27% to $1.29. The company's market cap stands at $19.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 11.76% to $1.9. The company's market cap stands at $4.6 million.
    • Autonomix Medical (NASDAQ:AMIX) shares increased by 11.66% to $3.35. The market value of their outstanding shares is at $63.0 million.
    • Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 11.65% to $1.82. The market value of their outstanding shares is at $135.9 million. As per the news, the Q4 earnings report came out 2 days ago.

    Losers

    • Better Therapeutics (NASDAQ:BTTX) stock fell 82.4% to $0.04 during Thursday's regular session. The market value of their outstanding shares is at $1.9 million.
    • Spruce Biosciences (NASDAQ:SPRB) stock fell 79.57% to $1.06. The market value of their outstanding shares is at $43.1 million. As per the news, the Q4 earnings report came out yesterday.
    • Immuneering (NASDAQ:IMRX) stock fell 48.73% to $3.02. The market value of their outstanding shares is at $88.2 million.
    • Sonida Senior Living (NYSE:SNDA) shares fell 26.43% to $19.0. The market value of their outstanding shares is at $219.1 million.
    • iSpecimen (NASDAQ:ISPC) shares fell 22.57% to $0.36. The market value of their outstanding shares is at $3.2 million. The company's, Q4 earnings came out yesterday.
    • TRACON Pharma (NASDAQ:TCON) shares decreased by 22.48% to $0.49. The company's market cap stands at $22.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $APM
    $BTTX
    $CLSD

    CompanyDatePrice TargetRatingAnalyst
    Sonida Senior Living Inc.
    $SNDA
    1/9/2026Neutral
    Robert W. Baird
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025$2.00Buy → Hold
    Stifel
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AMIX
    $APM
    $BTTX
    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Sonida Senior Living

    Robert W. Baird initiated coverage of Sonida Senior Living with a rating of Neutral

    1/9/26 9:07:37 AM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    Oppenheimer initiated coverage on Spruce Biosciences with a new price target

    Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00

    12/23/25 8:47:57 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00

    12/3/25 8:26:32 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    SEC Filings

    View All

    SEC Form 424B5 filed by Spruce Biosciences Inc.

    424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    3/9/26 7:31:48 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Spruce Biosciences Inc.

    S-8 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    3/9/26 7:29:22 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Spruce Biosciences Inc.

    10-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    3/9/26 7:21:45 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Hooks Corwin Dale

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    3/9/26 4:08:18 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hooks Corwin Dale

    3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    3/9/26 4:07:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)

    5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    2/17/26 8:30:02 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $APM
    $BTTX
    $CLSD
    Financials

    Live finance-specific insights

    View All

    Sonida Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in communities and services for seniors, announced today that it will issue its fourth quarter and full year 2025 earnings results before the market opens for trading on Wednesday, March 11, 2026. The Company will then host a conference call and webcast to review its financial performance and operating results at 4:30 p.m. Eastern Time. The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes

    3/6/26 5:00:00 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care